VM
ALLO icon

VV Manager’s Allogene Therapeutics ALLO Stock Holding History

VV Manager’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$77M Sell
1,798,163
-492,553
-22% -$17.8M 67.53% 1
2020
Q1 		$44.5M Sell
2,290,716
-598,935
-21% -$14.3M 50.32% 1
2019
Q4 		$75.1M Sell
2,889,651
-1,197,870
-29% -$33M 59.81% 1
2019
Q3 		$111M Sell
4,087,521
-1,796,805
-31% -$51.2M 82.89% 1
2019
Q2 		$158M Sell
5,884,326
-1,796,807
-23% -$50.1M 85.68% 1
2019
Q1 		$222M Hold
7,681,133
– – 87.16% 1
2018
Q4 		$207M Buy
+7,681,133
New +$204M 88.75% 1

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VV Manager's ALLO Position: Q2 2020 in Review

VV Manager reduced its Allogene Therapeutics (ALLO) stake by 22% in Q2 2020, selling an estimated $17.8M and leaving 1,798,163 shares worth $77M. The position accounts for 67.53% of the portfolio, ranked #1.

VV Manager first reported a position in ALLO in Q4 2018 and has held it in 7 quarters since. The position peaked at $222M in Q1 2019. 173 funds tracked by Wall St. Rank hold ALLO as of Q2 2020.

  • VV Manager held 1,798,163 shares of Allogene Therapeutics worth $77M as of Q2 2020.
  • VV Manager sold 492,553 Allogene Therapeutics shares in Q2 2020, an estimated $17.8M.
  • Allogene Therapeutics made up 67.53% of VV Manager's portfolio in Q2 2020, its #1 holding.
  • VV Manager first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 7 quarters since.
  • VV Manager's Allogene Therapeutics position peaked at $222M in Q1 2019.
  • 173 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2020.

Based on VV Manager's 13F filing for Q2 2020, filed 4 Aug 2020.